Walnut Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 1.86%
- Profit Growth -27.79%
- Ebitda 220.74%
- Net Worth 24.25%
- Total Assets 33.34%
About Walnut Pharma
Walnut Pharma Private Limited (WPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 April 2014 and has a history of Ten years and nine months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chirag Gosalia, Anujkumar Gupta, and Kirankumar Patel serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U85100GJ2014PTC079507
- Company No.
079507
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Apr 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Walnut Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chirag Gosalia  | Director | 01-Apr-2014 | Current |
| Anujkumar Gupta | Director | 01-Apr-2014 | Current |
| Kirankumar Patel | Director | 01-Apr-2014 | Current |
Financial Performance of Walnut Pharma.
Walnut Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.86% increase. The company also saw a substantial fall in profitability, with a 27.79% decrease in profit. The company's net worth Soared by an impressive increase of 24.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Walnut Pharma?
Unlock access to Walnut Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Arya Healthcare And Hygiene LimitedKirankumar Patel is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Walnut Pharma?
Walnut Pharma has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Walnut Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Walnut Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.